Trikafta Patent Protection
60 patents · Vertex Pharmaceuticals Inc.
Reviewed by PatentCliff Editorial Team · Updated
B
Patent Strength
68/100
60
Total Patents
1
Assignees
2027
Earliest Expiration
2043
Latest Expiration
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 8354427 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jan 6, 2027 | 0.5y left |
| 9974781 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Apr 9, 2027 | 0.8y left |
| 11639347 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Apr 9, 2027 | 0.8y left |
| 10239867 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Apr 9, 2027 | 0.8y left |
| 10022352 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Apr 9, 2027 | 0.8y left |
| 8598181 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | May 1, 2027 | 0.8y left |
| 8623905 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | May 1, 2027 | 0.8y left |
| 7645789 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | May 1, 2027 | 0.8y left |
| 7973038 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | May 8, 2027 | 0.9y left |
| 8741933 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | May 8, 2027 | 0.9y left |
| 9216969 | Drug substance & product patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | May 8, 2027 | 0.9y left |
| 7776905 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Jun 3, 2027 | 0.9y left |
| 9670163 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 28, 2027 | 1.0y left |
| 8410274 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 28, 2027 | 1.0y left |
| 8754224 | Drug substance & product patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 28, 2027 | 1.0y left |
| 9931334 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 28, 2027 | 1.0y left |
| 8415387 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Nov 12, 2027 | 1.4y left |
| 7495103 | Drug substance & product patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Nov 20, 2027 | 1.4y left |
| 8324242 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Feb 5, 2028 | 1.6y left |
| 9150552 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 10597384 | Drug substance & product patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 12065432 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 8653103 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 10076513 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 11052075 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 4, 2029 | 2.9y left |
| 8846718 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jan 2, 2030 | 3.5y left |
| 11564916 | Orange Book listed patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Feb 13, 2030 | 3.6y left |
| 12458635 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Feb 13, 2030 | 3.6y left |
| 10646481 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Feb 13, 2030 | 3.6y left |
| 9192606 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Mar 29, 2030 | 3.8y left |
| 8716338 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Mar 20, 2031 | 4.7y left |
| 8507534 | Drug substance & product patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Mar 20, 2031 | 4.7y left |
| 10081621 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Mar 25, 2031 | 4.7y left |
| 11578062 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Mar 25, 2031 | 4.7y left |
| 8993600 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Jun 11, 2031 | 5.0y left |
| RE50453 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Jul 10, 2031 | 5.0y left |
| 9181192 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | May 17, 2032 | 5.9y left |
| 9512079 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | May 17, 2032 | 5.9y left |
| 8865902 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | May 17, 2032 | 5.9y left |
| 10047053 | Drug substance (composition of matter) patent | Vertex Pharmaceuticals Inc. | May 17, 2032 | 5.9y left |
| 9012496 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Jul 15, 2033 | 7.1y left |
| 10058546 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Jul 15, 2033 | 7.1y left |
| 10272046 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Aug 27, 2033 | 7.2y left |
| 11147770 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Aug 27, 2033 | 7.2y left |
| 12214083 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Aug 27, 2033 | 7.2y left |
| 11752106 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Aug 27, 2033 | 7.2y left |
| 8883206 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Vertex Pharmaceuticals Inc. | Aug 27, 2033 | 7.2y left |
| 11951212 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Apr 14, 2035 | 8.8y left |
| 10206877 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Apr 14, 2035 | 8.8y left |
| 10758534 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Oct 6, 2035 | 9.3y left |
| 11426407 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Oct 6, 2035 | 9.3y left |
| 11517564 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Dec 8, 2037 | 11.5y left |
| 10793547 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Dec 8, 2037 | 11.5y left |
| 11179367 | Drug product (formulation / method-of-use) patent | Vertex Pharmaceuticals Inc. | Dec 8, 2037 | 11.5y left |
| 11453655 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Dec 8, 2037 | 11.5y left |
| 12350262 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Jul 17, 2038 | 12.1y left |
| 11866450 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Feb 14, 2039 | 12.6y left |
| 11066417 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Feb 14, 2039 | 12.6y left |
| 11873300 | Drug substance & product patent | Vertex Pharmaceuticals Inc. | Aug 13, 2040 | 14.1y left |
| 12186306 | Orange Book listed patent | Vertex Pharmaceuticals Inc. | Jan 10, 2043 | 16.5y left |
Related Drug Patent Expirations
Eliquis Patent Expiration
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
Entresto Patent Expiration
6 patents · earliest expires 2027 · Novartis AG
Ibrance Patent Expiration
3 patents · earliest expires 2027 · Pfizer Inc.
Imbruvica Patent Expiration
44 patents · earliest expires 2027 · Pharmacyclics LLC
Jardiance Patent Expiration
15 patents · earliest expires 2027 · Boehringer Ingelheim
Lynparza Patent Expiration
12 patents · earliest expires 2027 · AstraZeneca AB
For Trikafta, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Trikafta’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.